On September 1, 2021 Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, reported that company management will participate in three virtual investor conferences in September 2021 (Press release, Shattuck Labs, SEP 1, 2021, View Source [SID1234591768]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Conference: Citi 16th Annual BioPharma Virtual Conference
Format: Panel Discussion, "Framing the Tip of the Spear for Novel Antibodies and Protein Therapeutics"
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: September 9, 2021
Time: 1:25 p.m. EST

Conference: H.C. Wainwright 23rd Annual Global Investment Conference
Format: Corporate Presentation
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: September 13, 2021
Time: 7:00 a.m. EST

Conference: Morgan Stanley 19th Annual Global Healthcare Conference
Format: Fireside Chat
Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer and Andrew Neill, M.B.A., Shattuck’s Chief Financial Officer
Date: September 15, 2021
Time: 11:45 a.m. EST

A live webcast of the panel discussion, corporate presentation, and fireside chat will be available on the Events & Presentations section of the Company’s website. A replay of the webcasts will be archived for up to 90 days following the presentation date.

On September 1, 2021 PHYNOVA Group Ltd ("Phynova") and Bioriginal Food & Science Corp ("Bioriginal") reported a partnership on Reducose, Phynova’s patented and clinically researched White Mulberry Leaf extract that supports significant lowering of post-meal blood sugar and insulin response (Press release, Phynova, SEP 1, 2021, View Source [SID1234587256]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The partnership will encompass both distribution to North American customers as well as joint promotion of the health benefits of Reducose. Bioriginal will serve customers with Reducose as a stand-alone ingredient or as a hero-ingredient in turn-key solutions.

Stephane Ducroux, CEO at Phynova, said: "We are excited to embark on our go-to-market partnership with Bioriginal in the North American market. Phynova’s strategy is to partner with market focused experts such as Bioriginal, who have a proven track record of building deep customer relationships, fast prototyping and turn-key solutions using ingredients with a strong science pedigree like Reducose.

Phynova produces Reducose 5%, a patented premium white mulberry leaf extract that can reduce the blood sugar and insulin response after a meal by up to 40%. Reducose is vegetarian, natural, allergen free and is backed by 6 human clinical studies. Most recently Phynova published the positive clinical trial results on Reducose in the peer-reviewed journal ‘Nutrition & Metabolism’. The full paper can be accessed here: View Source

"We are excited to partner with Phynova by bringing a unique ingredient into Bioriginal’s highly selective nutraceutical ingredient line", said Matt Phillips, Vice President of Sales at Bioriginal. "Phynova’s sustainable, unique and clinically researched white mulberry leaf extract perfectly complements our innovative ingredients portfolio and strengthens our offerings to the nutraceutical and food industries. We look forward to collaborating with Phynova and utilizing Reducose to formulate turnkey concepts – that our customers can quickly take to market – addressing consumer demands for a multitude of benefits."

On September 1, 2021 Thermo Fisher Scientific’s clinical sequencing business and AstraZeneca reported they will co-develop next-generation sequencing (NGS)-based companion diagnostics (CDx) to support AstraZeneca’s expanding portfolio of targeted therapies (Press release, Thermo Fisher Scientific, SEP 1, 2021, View Source [SID1234587231]). The companies will collaborate under a multiyear, global agreement.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"As the pipeline of targeted therapies expands, the availability of diagnostic tools that can interrogate multiple biomarkers simultaneously will ensure patients can be matched with the right therapies more rapidly – this is the promise of precision medicine," said Garret Hampton, president of clinical next-generation sequencing and oncology at Thermo Fisher Scientific. "Introduction of diagnostic tools early in the process of drug development can further facilitate the success of companion diagnostic development – and that’s what we’re doing with AstraZeneca."

NGS-based companion diagnostics are increasingly used to match patients with new therapies for cancer and other diseases. More than 90 percent of AstraZeneca’s clinical pipeline, across all main areas from oncology, cardiovascular and renal to metabolic and respiratory disease, are targeted precision medicine therapies.

"Using the latest diagnostic science allows us to match the best treatment to the patient," said Ruth March, senior vice president, precision medicine and biosamples, AstraZeneca. "This collaboration with Thermo Fisher offers the technology, expertise and ability to decentralize CDx tests to local healthcare providers across our global markets, which will help us identify more patients around the world who may benefit from treatments and effective patient care."

Thermo Fisher currently offers the only globally distributable NGS CDx solution approved and reimbursed by government and commercial insurers in more than 15 countries, including the U.S., multiple European nations, Japan, South Korea and the Middle East, and covering more than 550 million lives globally.

To expand global access to a growing list of precision medicine therapies, in 2019 Thermo Fisher introduced the Ion Torrent Genexus System*, the first fully-integrated NGS platform featuring an automated specimen-to-report workflow that economically delivers results in a single day. The company’s complete NGS workflow, powered by Ion AmpliSeq technology, includes multiple solutions for solid tumor biomarkers and liquid biopsy testing.

*Currently for Research Use Only. Not for use in diagnostic procedures.

On September 1, 2021 Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, reported that members of its senior management team will participate in the following September investor conferences (Press release, Prothena, SEP 1, 2021, View Source [SID1234587187]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 16th Annual BioPharma Virtual Conference on Wednesday, September 8, a fireside chat will be held at 9:45 AM ET and a panel discussion titled "What’s Next for Neurodegenerative Diseases" will be held at 11:35 AM ET
H.C. Wainwright 23rd Annual Global Investment Conference, on Monday, September 13, a fireside chat will be available on demand starting at 7:00 AM ET
Cantor Global Healthcare Conference on Monday, September 27, a fireside chat will be held at 11:20 AM ET
A live webcast for all events can be accessed through the investor relations section of the Company’s website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for at least 90 days following the presentation date.

On September 1, 2021 Biogen Inc. (Nasdaq: BIIB) reported that it will participate in a live Q&A at the Morgan Stanley 19th Annual Global Healthcare Conference (Press release, Biogen, SEP 1, 2021, View Source [SID1234587186]). The webcast will be live on Thursday, September 9, at 9:30 a.m. ET. To access the live webcast, please visit Biogen’s Investors section at investors.biogen.com. An archived version of the webcast will be available following the presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!